BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28855986)

  • 1. Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine.
    Chen C; He H
    Mol Clin Oncol; 2017 Oct; 7(4):525-528. PubMed ID: 28855986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Successful treatment with high-dose methotrexate/cytarabine regimen in a patient in SMILE regimen-resistant extranodal natural killer/T-cell lymphoma].
    Saburi M; Itani K; Nagamatsu K; Miyazaki Y; Otsuka E; Urabe S; Saburi Y
    Rinsho Ketsueki; 2014 Jan; 55(1):120-4. PubMed ID: 24492044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK/T Cell Lymphoma: Updates in Therapy.
    Suzuki R
    Curr Hematol Malig Rep; 2018 Feb; 13(1):7-12. PubMed ID: 29368155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
    Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
    J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
    Kako S; Izutsu K; Oshima K; Sato H; Kanda Y; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2007 Oct; 82(10):937-9. PubMed ID: 17663389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case report of primary cutaneous natural killer/T-cell lymphoma.
    Tian C; Yu Y; Zhang Y
    Mol Clin Oncol; 2016 Dec; 5(6):777-778. PubMed ID: 28101356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.
    Kim SJ; Park S; Kang ES; Choi JY; Lim DH; Ko YH; Kim WS
    Ann Hematol; 2015 Jan; 94(1):71-8. PubMed ID: 25082384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis and treatment of extranodal natural killer/T-cell lymphoma.
    Suzuki R
    Semin Hematol; 2014 Jan; 51(1):42-51. PubMed ID: 24468315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature.
    McGehee E; Patel H; Pearson C; Clements K; Jaso JM; Chen W; Callan A; Desai N; Ramakrishnan Geethakumari P
    J Med Case Rep; 2021 Apr; 15(1):221. PubMed ID: 33926575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
    Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
    Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
    Yamaguchi M; Suzuki R; Oguchi M; Asano N; Amaki J; Akiba T; Maeda T; Itasaka S; Kubota N; Saito Y; Kobayashi Y; Itami J; Ueda K; Miyazaki K; Ii N; Tomita N; Sekiguchi N; Takizawa J; Saito B; Murayama T; Ando T; Wada H; Hyo R; Ejima Y; Hasegawa M; Katayama N
    J Clin Oncol; 2017 Jan; 35(1):32-39. PubMed ID: 28034070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Extranodal NK/T-cell lymphoma].
    Suzuki R
    Nihon Rinsho; 2014 Mar; 72(3):524-30. PubMed ID: 24724414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An aggressive primary orbital natural killer/T-cell lymphoma case: poor response to chemotherapy.
    Marchino T; Ibáñez N; Prieto S; Novelli S; Szafranska J; Mozos A; Graell X; Buil JA
    Ophthalmic Plast Reconstr Surg; 2014; 30(5):e131-4. PubMed ID: 24317101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage treatment improved survival of patients with relapsed extranodal natural killer/t-cell lymphoma, nasal type.
    Zhang XX; Xie CH; Xu Y; Deng D; Zhao YH; Zou BW; Zhou L; Li M; Wang J; Liu WP; Huang MJ
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):747-52. PubMed ID: 19304409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
    Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
    EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma.
    Makita S; Tobinai K
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):239-253. PubMed ID: 28340876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia.
    Jung KS; Cho SH; Kim SJ; Ko YH; Kang ES; Kim WS
    J Hematol Oncol; 2016 Apr; 9():41. PubMed ID: 27091029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus-associated natural killer/T-cell lymphomas.
    Asano N; Kato S; Nakamura S
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):15-21. PubMed ID: 23768637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.